Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Original Articles

Lack of Change of Lipoprotein(a) Levels by the Optimization of Glycemic Control With Insulin Therapy in NIDDM Patients

  1. Assumpta Caixàs, MD, PHD,
  2. Antonio Pérez, MD, PHD,
  3. Jordi Qrdóñez-Llanos, MD, PHD,
  4. Rosa Bonet, MSc,
  5. Mercedes Rigla, MD,
  6. Agustina Castellví, RN,
  7. L Bayén, MSc and
  8. Alberto De Leiva, Md, PHD
  1. Department of Endocrinology and Nutrition, Hospital de Sam Pau, Universitat Autdnoma de Barcelona Barcelona, Spain
  2. Department of Biochemistry (Lipid Section), Hospital de Sam Pau, Universitat Autdnoma de Barcelona Barcelona, Spain
  1. Address correspondence and reprint requests to Antonio Pérez Pérez, Servei d'Endocrinologia i Nutrició, Hospital de Sant Pau, Avda Sant Antoni Ma Claret, 167, 08025 Barcelona, Spain
Diabetes Care 1997 Sep; 20(9): 1459-1461. https://doi.org/10.2337/diacare.20.9.1459
PreviousNext
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

OBJECTIVE To evaluate the effect of glycemic control improvement with insulin therapy on lipoprotein(a) [Lp(a)] levels in patients with NIDDM.

RESEARCH DESIGN AND METHODS We performed a longitudinal study in a tertiary referral center to compare lipid and Lp(a) levels before and after 3 months of insulin therapy in 60 poorly controlled NIDDM patients (32 men, 28 women). Patients previously treated with oral hypoglycemic agents (n = 50) received one to two insulin doses, and those previously treated with insulin (n = 10) received multiple insulin doses. Lp(a) levels were measured by the Terumo method. Differences between the two periods were assessed by the paired t test and Wilcoxon's test.

RESULTS After 3 months of insulin therapy, HbA1c decreased from 9.6 ± 1.9 to 6.0 ± 1.4% (P < 0.0005) in all patients and from 9.1 ± 2.1 to 6.1 ± 2.9% (P < 0.05) in patients under multiple insulin doses, being ≤ 6.0% in 59% of patients. Total triglyceride and VLDL cholesterol levels decreased (P < 0.01) and HDL cholesterol increased significantly (P < 0.0005). However, no changes in Lp(a) levels were observed in all patients (25.3 ± 25.0 vs 25.7 ± 27.2% mg/dl) and in patients with baseline Lp(a) levels above (63.5 ± 15.5 vs. 65.1 ± 23.1 mg/dl) or below 30 mg/dl (11.5 ± 7.5 vs. 11.5 ± 7.3 mg/dl). In addition, patients reaching HbA1c levels ≤ 6.0% or > 6.0% presented similar Lp(a) levels (26.0 ± 29.1 vs 25.3 ± 25.0 mg/dl). Moreover, no correlations were observed between changes in Lp(a) levels and in the glycemic control parameters.

CONCLUSIONS This study shows that the improvement of glycemic control by insulin therapy does not influence plasma Lp(a) levels, measured by the Terumo method, in NIDDM patients, independently of baseline values and the degree of glycemic control reached.

  • Received December 31, 1996.
  • Accepted May 16, 1997.
  • Copyright © 1997 by the American Diabetes Association

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this Issue

September 1997, 20(9)
  • Table of Contents
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Lack of Change of Lipoprotein(a) Levels by the Optimization of Glycemic Control With Insulin Therapy in NIDDM Patients
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Lack of Change of Lipoprotein(a) Levels by the Optimization of Glycemic Control With Insulin Therapy in NIDDM Patients
Assumpta Caixàs, Antonio Pérez, Jordi Qrdóñez-Llanos, Rosa Bonet, Mercedes Rigla, Agustina Castellví, L Bayén, Alberto De Leiva
Diabetes Care Sep 1997, 20 (9) 1459-1461; DOI: 10.2337/diacare.20.9.1459

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Lack of Change of Lipoprotein(a) Levels by the Optimization of Glycemic Control With Insulin Therapy in NIDDM Patients
Assumpta Caixàs, Antonio Pérez, Jordi Qrdóñez-Llanos, Rosa Bonet, Mercedes Rigla, Agustina Castellví, L Bayén, Alberto De Leiva
Diabetes Care Sep 1997, 20 (9) 1459-1461; DOI: 10.2337/diacare.20.9.1459
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

Original Articles

  • Obstetric Management in Gestational Diabetes
  • Prevention of Type 2 Diabetes in Women With Previous Gestational Diabetes
  • Cellular Mechanisms for Insulin Resistance in Normal Pregnancy and Gestational Diabetes
Show more Original Articles

Pathophysiology/Complications

  • Obstructive Sleep Apnea, Glucose Tolerance, and β-Cell Function in Adults With Prediabetes or Untreated Type 2 Diabetes in the Restoring Insulin Secretion (RISE) Study
  • Importance of Intestinal Environment and Cellular Plasticity of Islets in the Development of Postpancreatectomy Diabetes
  • Impact of Type 1 Diabetes in the Developing Brain in Children: A Longitudinal Study
Show more Pathophysiology/Complications

Similar Articles

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.